Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

Bluestar’s epigenomic platform IDs breast, pancreatic cancer
Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning algorithms

Read the full 358 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE